[go: up one dir, main page]

WO2003013420A3 - Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification - Google Patents

Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification Download PDF

Info

Publication number
WO2003013420A3
WO2003013420A3 PCT/EP2002/008917 EP0208917W WO03013420A3 WO 2003013420 A3 WO2003013420 A3 WO 2003013420A3 EP 0208917 W EP0208917 W EP 0208917W WO 03013420 A3 WO03013420 A3 WO 03013420A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
prevention
treatment
osteoporosis
women
Prior art date
Application number
PCT/EP2002/008917
Other languages
French (fr)
Other versions
WO2003013420A2 (en
Inventor
Ceer Vermeer
Original Assignee
Vitak Bv
Ceer Vermeer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitak Bv, Ceer Vermeer filed Critical Vitak Bv
Priority to AU2002333378A priority Critical patent/AU2002333378A1/en
Priority to EP02794586A priority patent/EP1414387A2/en
Publication of WO2003013420A2 publication Critical patent/WO2003013420A2/en
Publication of WO2003013420A3 publication Critical patent/WO2003013420A3/en
Priority to US10/770,991 priority patent/US20050176778A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/10—Quinones the quinoid structure being part of a condensed ring system containing two rings
    • C07C50/14—Quinones the quinoid structure being part of a condensed ring system containing two rings with unsaturation outside the ring system, e.g. vitamin K1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/616—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A non-toxic biologically active compound is provided having the following general formula (I), wherein n is an integer from 1 to 14, preferably from 2 to 4, and R is an organic moiety, preferably a group different from but structurally substantially similar to 2-methyl naphthoquinone, or a group P-C(R1)-P, where each P stands for a -PO(OH)2 group and R1 is a (poly)isoprenyl group, hydroxy, halogen (preferably chloro or bromo), or hydrogen, or a pharmaceutically acceptable derivative thereof. These compounds are useful for the treatment or prevention of certain disorders in a mammal, especially a human being, for example postmenopausal loss of bone in women, juvenile or senile osteoporosis in men and women, cardiovascular calcification and other ectopic calcifications.
PCT/EP2002/008917 2001-08-03 2002-08-05 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification WO2003013420A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002333378A AU2002333378A1 (en) 2001-08-03 2002-08-05 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
EP02794586A EP1414387A2 (en) 2001-08-03 2002-08-05 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
US10/770,991 US20050176778A1 (en) 2001-08-03 2004-02-02 Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202955.9 2001-08-03
EP01202955 2001-08-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/770,991 Continuation US20050176778A1 (en) 2001-08-03 2004-02-02 Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification

Publications (2)

Publication Number Publication Date
WO2003013420A2 WO2003013420A2 (en) 2003-02-20
WO2003013420A3 true WO2003013420A3 (en) 2003-11-06

Family

ID=8180752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008917 WO2003013420A2 (en) 2001-08-03 2002-08-05 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification

Country Status (3)

Country Link
EP (1) EP1414387A2 (en)
AU (1) AU2002333378A1 (en)
WO (1) WO2003013420A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361001T1 (en) 2000-05-12 2007-05-15 Vitak Bv FOODS CONTAINING VITAMIN K2
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
DK1728507T4 (en) † 2005-06-03 2015-01-12 Nattopharma Asa The use of vitamin K to reverse calcification of the blood vessel
GB2476644B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
KR20140039141A (en) * 2010-12-17 2014-04-01 비택 비.브이. Use of vitamin k for weight maintenance and weight control

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243849A2 (en) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Process for the production of polyprenoid type compounds
EP0636598A1 (en) * 1993-07-26 1995-02-01 Eisai Chemical Co., Ltd. Preparation process of naphthoquinone derivatives and intermediates for the preparation thereof
WO1999000135A1 (en) * 1997-06-28 1999-01-07 The Boots Company Plc Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243849A2 (en) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Process for the production of polyprenoid type compounds
EP0636598A1 (en) * 1993-07-26 1995-02-01 Eisai Chemical Co., Ltd. Preparation process of naphthoquinone derivatives and intermediates for the preparation thereof
WO1999000135A1 (en) * 1997-06-28 1999-01-07 The Boots Company Plc Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product

Also Published As

Publication number Publication date
AU2002333378A1 (en) 2003-02-24
EP1414387A2 (en) 2004-05-06
WO2003013420A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
BE2011C002I2 (en) Aminocyclohexyl ether compounds and uses thereof
CA2129288A1 (en) Phosphonooxymethyl Esters of Taxane Derivatives
CA2259012A1 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AUPQ008299A0 (en) Isoflavone metabolites
AU2291001A (en) Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO1999019296A8 (en) Aminobutanoic acid derivatives
HK1038744A1 (en) Compounds useful in the treatment of inflammatory diseases
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
GB0117095D0 (en) "Process for the preparation of pure citalopram"
CA2325933A1 (en) Fatty acid derivatives of bile acids and bile acid derivatives
CA2336853A1 (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
AU1266900A (en) Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumors
DE69429173D1 (en) Taxolderivate
WO2000021910A3 (en) 1,2-disubstituted cyclopropanes
AU1182702A (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
WO2003013420A3 (en) Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
IL132599A0 (en) Substituted 3,3-diamino-2-propenenitriles their preparation and use
CA2204747A1 (en) New azo derivatives of 5-aminosalicylic acid
CA2218887A1 (en) Piperazino derivatives as neurokinin antagonists
EP1900741A8 (en) New process for the production of oxabispidines
WO2002026732A1 (en) Benzodiazepine derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002794586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10770991

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002794586

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP